Immunity: Experimental Transfer

Abstract

Transfers of biological reagents, cellular or humoral, have been a central theme in experimental immunology, including many areas of tumour immunology. Such transfers include lymphokine‐activated killer (LAK) cells, tumour‐infiltrating lymphocytes (TILs) and antigen‐specific cytotoxic T‐cell (CTL) lines and clones, monoclonal antibodies (mAbs) and cytokines.

Keywords: T lymphocytes; cytokines; tumour immunology; allotolerance; chronic inflammation

References

Bregenholt S, Delbro D and Claësson MH (1997) T cell transfer and TCR/cytokine gene deletion models in the study of inflammatory bowel disease. APMIS 105: 655–662.

Cheever MA, Thompson DB, Klarnet JP and Greenberg PD (1986) Antigen‐driven long term‐cultured T cells proliferate in vivo, distribute widely, mediate specific tumor therapy, and persist long‐term as functional memory T cells. Journal of Experimental Medicine 163: 1100–1112.

Embleton MJ, Charleston A, Robins RA, Pimm MV and Baldwin RW (1991) Recombinant ricin toxin A chain cytotoxicity against carcinoembryonic antigen expressing tumour cells mediated by a bispecific monoclonal antibody and its potentiation by ricin toxin B chain. British Journal of Cancer 63: 670–674.

Finkelman FD and Maliszewski C (1997) Enhancing cytokine effects in vivo. Immunologist 5: 10–14.

Gajewski TF, Fallarino F, Uyttenhove C and Boon T (1996) Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7‐1 over B7‐2 for active tumor immunization. Journal of Immunology 156: 2909–2917.

Henderson RA and Finn OJ (1996) Human tumor antigens are ready to fly. Advances in Immunology 62: 217–256.

Jacobsen IM and Claësson MH (1998) Veto cell suppression mechanisms in prevention of allograft rejection. APMIS 106: 345–353.

Jicha DL, Mule JJ and Rosenberg SA (1991) Interleukin 7 generates antitumor cytotoxic T lymphocytes against murine sarcomas with efficacy in cellular adoptive immunotherapy. Journal of Experimental Medicine 174: 1511–1515.

Kast WM, Offringa R, Peters PJ et al. (1989) Eradication of adenovirus E1‐induced tumors by E1A‐specific cytotoxic T lymphocytes. Cell 59: 603–614.

Kwon ED, Hurwitz AA, Foster BA et al. (1997) Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proceedings of the National Academy of Sciences of the USA 94: 8099–8103.

Lanzavecchia A (1998) Licence to kill. Nature 393: 413–414.

Nagy Z (1998) Immunological right of veto. Nature Biotechnology 16: 237–238.

Nielsen OH, Vainer B, Bregenholt S, Claësson MH, Bishop PD and Kirman I (1997) Inflammatory bowel disease: Potential and therapeutic strategies. Cytokines, Cellular and Molecular Therapy 3: 267–281.

Paleolog E (1997) Target effector role of vascular endothelium in the inflammatory response: insights from the clinical trial of anti‐TNF alpha antibody in rheumatoid arthritis. Molecular Pathology 50: 225–233.

Pardoll D (1992) Immunotherapy with cytokine gene‐transduced tumor cells: the next wave in gene therapy for cancer. Current Opinion in Oncology 4: 1124–1129.

Pardoll DM (1998) Cancer vaccines. Nature Medicine 4: 525–531.

Reimann J, Rudolphi A and Claësson MH (1995) Novel experimental approaches in the study of the immunopathology in inflammatory bowel disease. Journal of Molecular Medicine 73: 133–140.

Rosenberg SA and Lotze MT (1986) Cancer immunotherapy using interleukin‐2 and interleukin‐2‐activated lymphocytes. Annual Review of Immunology 4: 681–709.

Stenholm ACO, Kirkin A and Zeuthen J (1998) In vivo eradication of an established human melanoma by an in vitro generated autologous cytotoxic T cell clone: a scid mouse model. International Journal of Cancer 77: 476–480.

van de Winkel JGJ, Bast B and de Gast GC (1997) Immunotherapeutica potential of bispecific antibodies. Immunology Today 18: 562–564.

Waldmann H and Cobbold S (1998) How do monoclonal antibodies induce tolerance? A role for infectious tolerance? Annual Review of Immunology 16: 619–644.

Yee C, Riddell SR and Greenberg PD (1997) Prospects of adoptive T cell therapy. Current Opinion in Immunology 9: 702–708.

Further Reading

Culver WK (1994) Gene Therapy – A Handbook for Physicians. New York: Mary Ann Liebert.

Janeway CA and Travers P (1997) Immunobiology. Edinburgh: Current Biology, Churchill Livingstone 1997.

Roitt I, Brostoff J and Male D (1996) Immunology, 4th edn. London: Times Mirror International.

Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

How to Cite close
Claësson, Mogens H, and Hald, Jesper(Apr 2001) Immunity: Experimental Transfer. In: eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net [doi: 10.1038/npg.els.0001440]